CN103896900A - Compound with nerve protection function as well as preparation method and application of compound - Google Patents
Compound with nerve protection function as well as preparation method and application of compound Download PDFInfo
- Publication number
- CN103896900A CN103896900A CN201210594969.7A CN201210594969A CN103896900A CN 103896900 A CN103896900 A CN 103896900A CN 201210594969 A CN201210594969 A CN 201210594969A CN 103896900 A CN103896900 A CN 103896900A
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- neuroprotective
- cch
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 64
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- 210000005036 nerve Anatomy 0.000 title abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 230000000324 neuroprotective effect Effects 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 13
- 230000001537 neural effect Effects 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 239000003405 delayed action preparation Substances 0.000 claims description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000000860 cochlear nerve Anatomy 0.000 claims 1
- 210000003792 cranial nerve Anatomy 0.000 claims 1
- 210000000256 facial nerve Anatomy 0.000 claims 1
- 210000001328 optic nerve Anatomy 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 210000001032 spinal nerve Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- 239000000243 solution Substances 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 238000001914 filtration Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 238000004108 freeze drying Methods 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 9
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 6
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 5
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 5
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000012982 microporous membrane Substances 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N monoethanolamine hydrochloride Natural products NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 5
- 239000013618 particulate matter Substances 0.000 description 5
- -1 phosphatide Chemical compound 0.000 description 5
- 229960000502 poloxamer Drugs 0.000 description 5
- 229920001983 poloxamer Polymers 0.000 description 5
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 5
- 235000015320 potassium carbonate Nutrition 0.000 description 5
- 239000002510 pyrogen Substances 0.000 description 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 239000001119 stannous chloride Substances 0.000 description 5
- 235000011150 stannous chloride Nutrition 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- KNKFLSQIGYRZAQ-UHFFFAOYSA-N 1-iodo-3,3-dimethylbutane Chemical compound CC(C)(C)CCI KNKFLSQIGYRZAQ-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000007830 nerve conduction Effects 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- CJTZXIJETZZARD-UHFFFAOYSA-N 1-iodo-2,2-dimethylpropane Chemical compound CC(C)(C)CI CJTZXIJETZZARD-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 229940122459 Glutamate antagonist Drugs 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- LWLSVNFEVKJDBZ-UHFFFAOYSA-N N-[4-(trifluoromethoxy)phenyl]-4-[[3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methyl]piperidine-1-carboxamide Chemical compound FC(OC1=CC=C(C=C1)NC(=O)N1CCC(CC1)CC1=CC(=CC=C1)OC1=NC=C(C=C1)C(F)(F)F)(F)F LWLSVNFEVKJDBZ-UHFFFAOYSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003825 glutamate receptor antagonist Substances 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011806 microball Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a compound as well as a pharmaceutical composition, a preparation method and an application thereof. The application refers to the application in preparing a medicine with the nerve protection function. The use effect of the compound for protecting nerve is very remarkable.
Description
Technical field
The present invention relates to compound and pharmacologically acceptable salt and its analogue that a class has neuroprotective; the pharmaceutical composition of being prepared by above-claimed cpd and pharmacologically acceptable salt thereof and its analogue, and described compound or pharmaceutically acceptable salt thereof and analogue thereof have the purposes in the medicine of neuroprotective in preparation.
Background technology
Scientific circles, actively finding nerve protection medicine, use it for the nerve injury causing due to a variety of causes at present, exploitation nerve protection medicine, and the molecular mechanism of research neuroprotective is to be extensively subject to the hot issue that Chinese scholars is paid close attention at present.The importance of neuroprotective is well imagined; nearly hundred kinds of the medicines that has neuroprotective of reporting at present; conventional neuroprotective comprises calcium-channel antagonists, free-radical scavengers, glutamate antagonist, cell membrane stability agent etc.; but at present because pathogenesis is unintelligible; therefore very good neuroprotective so far does not produce effect; because patient colony is large and harm is large, need to develop a kind of medicine effectively with extraordinary neuroprotective.
The synthetic one group of new compound of the inventor and similar compound thereof or its pharmacologically acceptable salt have in preparation on the medicine of neuroprotective and have an unexpected effect, and have neuroprotective at present there is no report for this compounds.
Summary of the invention
The invention provides the preparation of one group of compound and similar compound or its pharmacologically acceptable salt and the new purposes in the medicine of preparing neuroprotective thereof.
Technical scheme of the present invention is as follows:
One compounds or its pharmacologically acceptable salt and analogue thereof, the structure of described compound is as follows:
Wherein R
1be selected from (CH
3)
3cCH
2cH
2-, (CH
3)
3cCH
2-, (CH
3)
3c-, R
2be selected from-OH-Br ,-H ,-CH
3,
Be selected from-CN of R3 ,-CONH
2,-COOC
2h
5.
The present invention has specifically prepared following 5 compounds:
Compound (A);
Compound (B);
Compound (C);
Compound (D);
Compound (E).
The synthetic route of compound of the present invention is as follows:
R
1?is?chosen?from(CH
3)
3CCH
2CH
2-，(CH
3)
3CCH
2-，(CH
3)
3C-.
R
2?is?chosen?from-OH，-Br，-H，-Me.
R
3?is?chosen?from-CN，-CONH
2，-COOEt.
Wherein R
1be selected from (CH
3)
3cCH
2cH
2-, (CH
3)
3cCH
2-, (CH
3)
3c-, R
2be selected from-OH-Br ,-H ,-CH
3, be selected from-CN of R3 ,-CONH
2,-COOC
2h
5.
Compound or pharmaceutically acceptable salt thereof of the present invention and analogue thereof the purposes in the medicine of preparing neuroprotective, is specially the provide protection to peripheral nerve and nervus centralis.
Compound of the present invention and analogue thereof or its pharmacologically acceptable salt can be prepared into through topical, the various preparations of gastrointestinal administration or parenteral administration.Described preparation comprises ordinary preparation, controlled release preparation, targeting preparation etc.Described local administration preparation is through the powder injection of organ administration, aqueous injection, microball preparation, nanometer formulation, Liposomal formulation, dendrimer preparation, polyethyleneglycol modified preparation, aqueogel etc.Described parenteral administration preparation is the formulation of suitable intravenous injection, intramuscular injection, subcutaneous injection, bone marrow injection, transdermal administration, mucosa delivery and inhalation.
The inventor studies discovery: this compounds has the effect of extraordinary neuroprotective, and from the result of pharmacodynamic experiment, the effect of the neuroprotective of this compounds exceeds the medicine of current clinical application.The exploitation of this new compound will be for removing sufferer misery, and the quality of life that improves patient contributes.
Accompanying drawing explanation
Fig. 1: the nuclear magnetic spectrum of compound (A).
Fig. 2: the nuclear magnetic spectrum of compound (B).
Fig. 3: the nuclear magnetic spectrum of compound (C).
Fig. 4: the nuclear magnetic spectrum of compound (D).
Fig. 5: the nuclear magnetic spectrum of compound (E).
Embodiment
Preparation Example
Preparation Example 1 (compd A is the preparation of compd A 4)
Compd A 1 and 1-iodo-2,2-dimethylpropane refluxes and generates compd A 2 in salt of wormwood, acetonitrile solution, compd A 2 refluxes and generates compound A-13 with Resorcinol, propane dinitrile in ethanol and triethylamine mixing solutions, and Sold Stannous Chloride Catalyzes compound A-13 normal-temperature reaction in ethanol solution hydrochloride generates compd A 4.
Preparation Example 2 (compd B is the preparation of compd B 4)
Compound B-11 and 1-iodo-3,3-dimethylbutane refluxes and generates compd B 2 in salt of wormwood, acetonitrile solution, compd B 2 refluxes and generates compd B 3 with p-cresol, propane dinitrile in ethanol and triethylamine mixing solutions, and Sold Stannous Chloride Catalyzes compd B 3 normal-temperature reaction in ethanol solution hydrochloride generates compd B 4.
Preparation Example 3 (Compound C is the preparation of Compound C 4)
Preparation Example 4 (Compound D is the preparation of Compound D 4)
Preparation Example 5 (compd E is the preparation of compd E 4)
Preparation containing compd A injection:
1. altogether 50mg and 100mg formula (A) compound mix and make it dissolving in water for injection to get N.F,USP MANNITOL, phosphatide, glycerine, cyclodextrin derivative, dimethyl sulfoxide (DMSO) and poloxamer;
2. after mixing dissolving, after stable, first use 0.45um millipore filtration coarse filtration, then use 0.2um filtering with microporous membrane;
3. be distributed into little cillin bottle, add other freeze-drying therapeutical agent and auxiliary materials;
4. carry out procedural freeze-drying;
5. carry out the corresponding inspections such as pyrogen, aseptic, visible foreign matters, particulate matter, stand-by after all meeting the requirements.
Preparation containing compd B injection:
1. altogether 50mg and 200mg formula (B) compound mix and make it dissolving in water for injection to get N.F,USP MANNITOL, phosphatide, glycerine, cyclodextrin derivative, dimethyl sulfoxide (DMSO) and poloxamer;
2. after mixing dissolving, after stable, first use 0.45um millipore filtration coarse filtration, then use 0.2um filtering with microporous membrane;
3. be distributed into little cillin bottle, add other freeze-drying therapeutical agent and auxiliary materials;
4. carry out procedural freeze-drying;
5. carry out the corresponding inspections such as pyrogen, aseptic, visible foreign matters, particulate matter, stand-by after all meeting the requirements.
Preparation containing Compound C injection:
1. altogether 50mg and 20mg formula (C) compound mix and make it dissolving in water for injection to get N.F,USP MANNITOL, phosphatide, glycerine, cyclodextrin derivative, dimethyl sulfoxide (DMSO) and poloxamer;
2. after mixing dissolving, after stable, first use 0.45um millipore filtration coarse filtration, then use 0.2um filtering with microporous membrane;
3. be distributed into little cillin bottle, add other freeze-drying therapeutical agent and auxiliary materials;
4. carry out procedural freeze-drying;
5. carry out the corresponding inspections such as pyrogen, aseptic, visible foreign matters, particulate matter, stand-by after all meeting the requirements.
Preparation containing Compound D injection:
1. altogether 50mg and 50mg formula (D) compound mix and make it dissolving in water for injection to get N.F,USP MANNITOL, phosphatide, glycerine, cyclodextrin derivative, dimethyl sulfoxide (DMSO) and poloxamer;
2. after mixing dissolving, after stable, first use 0.45um millipore filtration coarse filtration, then use 0.2um filtering with microporous membrane;
3. be distributed into little cillin bottle, add other freeze-drying therapeutical agent and auxiliary materials;
4. carry out procedural freeze-drying;
5. carry out the corresponding inspections such as pyrogen, aseptic, visible foreign matters, particulate matter, stand-by after all meeting the requirements.
Preparation containing compd E injection:
1. get N.F,USP MANNITOL, phosphatide, glycerine, cyclodextrin derivative, dimethyl sulfoxide (DMSO) and poloxamer 50mg and 80mg altogether
Formula (E) compound in water for injection, mix and make it dissolve;
2. after mixing dissolving, after stable, first use 0.45um millipore filtration coarse filtration, then use 0.2um filtering with microporous membrane;
3. be distributed into little cillin bottle, add other freeze-drying therapeutical agent and auxiliary materials;
4. carry out procedural freeze-drying;
5. carry out the corresponding inspections such as pyrogen, aseptic, visible foreign matters, particulate matter, stand-by after all meeting the requirements.
Effect embodiment
Medicine A-E is to neural provide protection
1 Animal Model and administration
Healthy adult new zealand rabbit, body weight 2kg, male and female half and half.Method according to Luo Wenlong, Zhou Cuiying report is carried out modeling (Initial Experiment of the pHGF opposite repairing of neural injury effect of Chongqing Medical the 32nd the 3rd phase of volume of March in 2003).Preoperative normal raising, postoperative routine gives penicillin 1 abdominal injection every day.Give new zealand rabbit Chloral Hydrate intraperitoneal injection of anesthesia by 500mg/kg body weight, expose and the about 1.5cm of the neural upper buccal branches of surface of separation, cross-section and cut 0.2cm.Two broken ends of fractured bone embed the each 0.2cm of the long silicone tube of 1cm (external diameter 3mm, internal diameter 2mm), merge fixing silicone tube in epineurium along 120 degree clearance gaps with 9-0 silk thread, form the gap of about 6mm between two broken ends of fractured bone, wherein the injection solution (5mg injection) of micro sample adding appliance injection of medicine A-E is used respectively on rabbit right side, every kind of medicine carries out 10 rabbit experiments, every rabbit right nervus lateralis is as medicine group, the physiological saline that equal volume amounts is all injected in left side is as model control group, stroke-physiological saline solution flush operation chamber, 4-0 silk thread layer-by-layer suture otch.
2 experiment calibratings
The detection of 2.1 nerve conduction velocity
Postoperative one month, all rabbit are anaesthetized, and enter along former otch, with the pin electrode dry proximal part that directly excites nerve, on its domination muscle, use concentric needle electrode record, calculate nerve conduction velocity and compound muscle action potential latent period.
The each group of table 1 drug treatment nerve conduction velocity comparative result (m/s, n=10) after month
With relatively * P < 0.05**P < 0.01 of model control group
The each group of table 2 drug treatment compound muscle action potential comparative result in latent period (s, n=10) after month
With relatively * P < 0.05**P < 0.01 of model control group
2.2 nervous tissue dyeing are observed
Get the nerve segment of the each 0.5cm of the nearly far-end of previous anastomotic, be fixed with 10% formalin, after dehydration, embedding, section, dyeing, examine under a microscope.According to the method for Luo Wenlong, Zhou Cuiying report, after taking pictures, with ias, Regenerating Axons quantity, diameter, area and myelin thickness etc. are measured.The results are shown in Table 3-5.
The each group of table 3 drug treatment regenerating nerve examine of diameter comparative result (um, n=10) after month
With relatively * P < 0.05**P < 0.01 of model control group
The each group of table 4 drug treatment after one month regenerating nerve have marrow aixs cylinder Area comparison result (um
2, n=10)
With relatively * P < 0.05**P < 0.01 of model control group
The each group of table 5 drug treatment after one month regenerating nerve have marrow aixs cylinder counting comparative result (n=10)
With relatively * P < 0.05**P < 0.01 of model control group
Comprehensive above-mentioned experimental result is reached a conclusion: compound (A), (B), (C), (D), the medicine of (E) preparing all plays extraordinary neuroprotective.
Claims (9)
1. a compounds or its pharmacologically acceptable salt and analogue thereof, the structure of described compound is as follows:
Wherein R
1be selected from (CH
3)
3cCH
2cH
2-, (CH
3)
3cCH
2-, (CH
3)
3c-, R
2be selected from-OH-Br ,-H ,-CH
3, be selected from-CN of R3 ,-CONH
2,-COOC
2h
5.
2. compound or pharmaceutically acceptable salt thereof claimed in claim 1 and analogue thereof, it is selected from following compound:
Compound (A);
Compound (B);
Compound (C);
Compound (D);
Compound (E).
3. the preparation method of compound described in any one claim in claim 1-2, is characterized by according to following route synthetic:
R
1?is?chosen?from(CH
3)
3CCH
2CH
2-，(CH
3)
3CCH
2-，(CH
3)
3C-.
R
2?is?chosen?from-OH，-Br，-H，-Me.
R
3?is?chosen?from-CN，-CONH
2，-COOEt.
Wherein R
1be selected from (CH
3)
3cCH
2cH
2-, (CH
3)
3cCH
2-, (CH
3)
3c-, R
2be selected from-OH-Br ,-H ,-CH
3, be selected from-CN of R3 ,-CONH
2,-COOC
2h
5.
4. compound or pharmaceutically acceptable salt thereof and the purposes of analogue in the medicine of preparing neuroprotective thereof described in claim 1-3 any one.
5. application described in claim 4, described neuroprotective refers to comprising the unify neuroprotective of peripheral nervous system of central nervous system.
6. application described in claim 5, described neuroprotective refers to the protection neural to facial nerve, auditory nerve, optic nerve, cranial nerve, spinal nerves etc.
As claimed in claim 6 application, described neuroprotective for be people, animal and cell etc.
8. the pharmaceutical composition that comprises any one compound or pharmaceutically acceptable salt thereof in claim 1-7 and analogue thereof, is characterized in that this pharmaceutical composition to be prepared into ordinary preparation, controlled release preparation or targeting preparation.
9. the pharmaceutical composition of claim 8, described compound and pharmacologically acceptable salt thereof and its analogue are prepared into through topical, the various preparations of gastrointestinal administration or parenteral administration.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210594969.7A CN103896900A (en) | 2012-12-25 | 2012-12-25 | Compound with nerve protection function as well as preparation method and application of compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210594969.7A CN103896900A (en) | 2012-12-25 | 2012-12-25 | Compound with nerve protection function as well as preparation method and application of compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103896900A true CN103896900A (en) | 2014-07-02 |
Family
ID=50988521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210594969.7A Pending CN103896900A (en) | 2012-12-25 | 2012-12-25 | Compound with nerve protection function as well as preparation method and application of compound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103896900A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006026832A1 (en) * | 2004-09-09 | 2006-03-16 | Howard Florey Institute Of Experimental Physiology And Medicine | Enzyme inhibitors and uses thereof |
| WO2009065169A1 (en) * | 2007-11-19 | 2009-05-28 | Howard Florey Institute | Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof |
| CN103896899A (en) * | 2012-12-25 | 2014-07-02 | 韩冰 | Compounds for reducing intraocular pressure and preparation method and application thereof |
-
2012
- 2012-12-25 CN CN201210594969.7A patent/CN103896900A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006026832A1 (en) * | 2004-09-09 | 2006-03-16 | Howard Florey Institute Of Experimental Physiology And Medicine | Enzyme inhibitors and uses thereof |
| WO2009065169A1 (en) * | 2007-11-19 | 2009-05-28 | Howard Florey Institute | Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof |
| CN103896899A (en) * | 2012-12-25 | 2014-07-02 | 韩冰 | Compounds for reducing intraocular pressure and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2846823T3 (en) | Organic compounds | |
| ES2210359T3 (en) | COMPOSITIONS FOR THE TREATMENT OF PAIN. | |
| CA2781436C (en) | Arachidonic acid analogs and methods for analgesic treatment using same | |
| CN1308530A (en) | Use of tricyclic antidepressants for local analgesia | |
| Chen et al. | Injectable electrospun fiber-hydrogel composite sequentially releasing clonidine and ropivacaine for prolonged and walking regional analgesia | |
| CN109562281A (en) | The prodrug of phenols TRPV1 agonist is combined with local anesthetic and vasoconstrictor for improving local anaesthesia | |
| KR20100062990A (en) | Injectable polymer-lipid blend for localized drug delivery | |
| JP2004521112A (en) | Use of a neurotoxic substance in manufacturing a therapeutic agent for joint pain | |
| JP2015205923A (en) | Pain control pharmaceutical composition | |
| CN111214469B (en) | Compounds for preventing and treating chronic pain and their applications | |
| BR112021004661A2 (en) | compound, pharmaceutical composition, method for treating neuropathic pain and/or pruritus, and use of the compound | |
| CN103896900A (en) | Compound with nerve protection function as well as preparation method and application of compound | |
| CN103804351A (en) | Compound with neuroprotective effect and use thereof | |
| CN103804363A (en) | Compound with neuroprotective effect and use thereof | |
| CN103804272A (en) | Compound with neuroprotective effect and use thereof | |
| ES2991018T3 (en) | (N-(2-((2-benzylphenyl)amino)-2-oxoethyl)-L-naphthamide) as an anticancer therapeutic agent | |
| CN103804299A (en) | Compound with neuroprotective effect and use thereof | |
| CN103864797A (en) | Compounds with nerve protection function and application thereof | |
| ES2930757T3 (en) | A drug formulation for use in the effective control of acute and/or chronic pain | |
| CN104370881A (en) | Neuroprotective effect compound and preparation method and use thereof | |
| CN104370926A (en) | Neuroprotective effect compound and preparation method and use thereof | |
| CN103845330A (en) | Compound for reducing intraocular pressure and application thereof | |
| CN104370888A (en) | Neuroprotective effect compound and preparation method and use thereof | |
| CN103896899A (en) | Compounds for reducing intraocular pressure and preparation method and application thereof | |
| Wang et al. | Synergistic DNA repair inhibition and genotoxic therapy in cisplatin-resistant tumors via microneedle-based co-delivery of PROTAC and Pt (IV) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140702 |